FDA
-
-
-
-
-
-
-
Knight Therapeutics Reports Fourth Quarter and Year-End 2021 Results and Provides 2022 Revenue Guidance
-
-
-
-
-
-
-
Knight and TherapeuticsMD (TXMD) Announce Health Canada Approval of IMVEXXY
-
-
-
-
-
-
-
Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight Therapeutics
-
-
-
-
-
-
-
Knight Therapeutics and Jaguar Health Announce Strategic Partnership
-
-
-
-
-
-
-
Knight Receives Adverse Notice of Reassessment from CRA
-
-
-
-
-
-
-
Knight Supports Crescita Trajectory
-
-
-
-
-
251,413 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All